Riccardo Danielli
Overview
Explore the profile of Riccardo Danielli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2071
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Orsini C, Santi F, Fiorani D, Sorrentino E, Malaspina L, Danielli R, et al.
Ital J Dermatol Venerol
. 2022 Aug;
157(4):386-387.
PMID: 35916188
No abstract available.
2.
Bersanelli M, Giannarelli D, Leonetti A, Buti S, Tiseo M, Nouvenne A, et al.
Future Oncol
. 2021 Feb;
17(9):1097-1104.
PMID: 33538178
We presented the rationale for the use of thymosin α1 as prophylaxis of severe COVID-19 in cancer patients undergoing active treatment, constituting the background for the PROTHYMOS study, a prospective,...
3.
Fizazi K, Drake C, Beer T, Kwon E, Scher H, Gerritsen W, et al.
Eur Urol
. 2020 Aug;
78(6):822-830.
PMID: 32811715
Background: The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received docetaxel previously. In...
4.
Chiarucci C, Cannito S, Daffina M, Amato G, Giacobini G, Cutaia O, et al.
Cancers (Basel)
. 2020 Feb;
12(2).
PMID: 32033266
Targeting of the programmed cell death protein (PD)-1/programmed death-ligand 1 (PD-L1) axis has shown a significant clinical impact in several tumor types. Accordingly, our phase II NIBIT-MESO-1 study demonstrated an...
5.
Di Giacomo A, Covre A, Finotello F, Rieder D, Danielli R, Sigalotti L, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7351-7362.
PMID: 31530631
Purpose: The immunomodulatory activity of DNA hypomethylating agents (DHAs) suggests they may improve the effectiveness of cancer immunotherapies. The phase Ib NIBIT-M4 trial tested this hypothesis using the next-generation DHA...
6.
Weide B, Eigentler T, Catania C, Ascierto P, Cascinu S, Becker J, et al.
Cancer Immunol Immunother
. 2019 Sep;
68(9):1547-1559.
PMID: 31482307
Engineered cytokine products represent promising agents for the treatment of immunogenic tumors, such as malignant melanoma, in addition to immune checkpoint inhibitors. Here we describe the results of a controlled,...
7.
Cinotti E, Fiorani D, Provvidenziale L, Miracco C, Calamai V, Danielli R, et al.
Int J Dermatol
. 2019 Feb;
58(7):e138-e140.
PMID: 30810218
No abstract available.
8.
Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B, et al.
Nat Med
. 2018 Oct;
24(12):1941.
PMID: 30291359
In the version of this article originally published, there was an error in Fig. 2n. The top line of the HR comparison chart originally was Atezo + bev vs sun....
9.
Danielli R, Cisternino F, Giannarelli D, Calabro L, Camerini R, Savelli V, et al.
Expert Opin Biol Ther
. 2018 Aug;
18(sup1):77-83.
PMID: 30063847
Background: Immune checkpoint blockade antibodies (imAbs), such as the anti Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) ipilimumab (IPI) raised overall survival (OS) in metastatic melanoma (MM). Further, long-term OS is a...
10.
Mcdermott D, Huseni M, Atkins M, Motzer R, Rini B, Escudier B, et al.
Nat Med
. 2018 Jun;
24(6):749-757.
PMID: 29867230
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib in 305 patients with treatment-naive metastatic renal cell carcinoma....